Germany: Fresenius Kabi buys majority stake in mAbxience and acquires Ivenix

Fresenius Kabi, the German healthcare company’s blood transfusion business, has taken a majority stake in mAbxience and acquired Ivenix to accelerate strategic growth in Biopharmaceuticals and MedTech. The transaction market the first steps in Fresenius Kabi executing its “Vision 2026” growth strategy. The 55% stake in mAbxience for an upfront €495m (US$546m), enhances Fresenius Kabi’s presence…

You must be a HMI Subscriber to view this content.

Subscribe Now »